News

Novartis announced that the US Food and Drug Administration (FDA) has approved Afinitor DISPERZ (everolimus tablets for oral suspension), for the adjunctive treatment of adult and…
Read More...

Charles River Laboratories International, Inc. and PathoQuest announced an expansion of their strategic partnership agreement to provide next-generation sequencing (NGS) services to the…
Read More...

Novartis announced that it has entered into an agreement and plan of merger with AveXis, Inc. to acquire the US-based Nasdaq-listed clinical stage gene therapy company for USD 218 per…
Read More...

Protalex, Inc. announced that the Company has enrolled the first of three patients in cohort four of its U.S./U.K. Phase 1/2 trial evaluating PRTX-100 for the treatment of adults with…
Read More...

Allele Biotechnology & Pharmaceuticals Inc. has received a Tissue Bank License from the California Department of Public Health, making it the world’s first establishment to collect…
Read More...

Eidos Therapeutics announced a $64.0 million Series B financing. Proceeds from the financing will be used to advance Eidos' small molecule product candidate, AG10, into Phase 2 clinical…
Read More...

AbbVie announced global resolution of all intellectual property-related litigation with Samsung Bioepis over its proposed biosimilar adalimumab product. Under the terms of the…
Read More...

Stemline Therapeutics announced that it has initiated its rolling submission of a Biologics License Application (BLA) for SL-401 to the U.S. Food and Drug Administration (FDA). SL-401…
Read More...

PhaseBio Pharmaceuticals announced that it has completed dosing in the first cohort of subjects in its Phase 1 clinical trial of PB2452 (formerly MEDI2452), a reversal agent for the…
Read More...

MyoKardia, Inc. announced that the first patient has been dosed in the company’s Phase 2 MAVERICK-HCM clinical trial. MAVERICK-HCM is the first clinical trial of mavacamten in…
Read More...

Agilent Technologies Inc. and Lasergen, Inc. (Lasergen) announced that they have signed a definitive agreement for Agilent to acquire the remaining shares of Lasergen, an emerging…
Read More...

Ferring Pharmaceuticals and Rebiotix Inc. announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative healthcare companies…
Read More...

Ubiquigent Limited announced that it has entered into a multi-year strategic R&D collaboration agreement with FORMA Therapeutics for the design and development of novel…
Read More...

Cardiva Medical announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication of the VASCADE Vascular Closure System.…
Read More...

Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in oncology, vaccines, and general medicine announced that it has signed a merger agreement with…
Read More...

Boehringer Ingelheim and OSE Immunotherapeutics announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist…
Read More...

Aradigm Corporation announced the completed formal validation by the European Medicines Agency (EMA) of the Marketing Authorisation Application (MAA) for Linhaliq for the treatment of…
Read More...

Versant Ventures announced that Roche Holdings Inc. has acquired the Inception 5 program, focused on regenerative therapies for multiple sclerosis. Financial terms are not disclosed.…
Read More...

Proteostasis Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the Company's triple combination program for the treatment of…
Read More...

Alkermes plc announced that it received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily,…
Read More...